AstraZeneca acquires DSM Biologics manufacturing facility in Canada
As announced in December 2005, DSM mothballed the Montreal facility as part of its strategy for DSM Biologics. Core to this strategy is the development and out-licensing of a new manufacturing technology platform based on the PER.C6® human cell line, in a joint venture with the Dutch biotechnology company Crucell N.V. DSM and its partner Crucell have recently announced a breakthrough in production yields, achieving 10g/L in the fermentation of monoclonal antibodies, using the PER.C6® technology platform, and stating a target of 20g/L for their near term development efforts.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous